Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
2.550
+0.200 (8.51%)
May 27, 2025, 3:40 PM - Market open
Aquestive Therapeutics Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Aquestive Therapeutics stock ranges from a low of $8.00 to a high of $17. The average analyst price target of $11.4 forecasts a 347.06% increase in the stock price over the next year.
Price Target: $11.40 (+347.06%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aquestive Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 6 | 6 | 6 | 5 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 7 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +292.16% | May 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +292.16% | Apr 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +292.16% | Mar 10, 2025 |
| Lake Street | Lake Street | Strong Buy Maintains $10 → $8 | Strong Buy | Maintains | $10 → $8 | +213.73% | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +292.16% | Dec 20, 2024 |
Financial Forecast
Revenue This Year
46.89M
from 57.56M
Decreased by -18.55%
Revenue Next Year
65.93M
from 46.89M
Increased by 40.62%
EPS This Year
-0.71
from -0.51
EPS Next Year
-0.64
from -0.71
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 53.2M | 78.7M | 154.4M | ||
| Avg | 46.9M | 65.9M | 99.9M | ||
| Low | 39.7M | 46.1M | 49.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -7.5% | 67.9% | 134.1% | ||
| Avg | -18.5% | 40.6% | 51.5% | ||
| Low | -31.1% | -1.8% | -24.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.64 | -0.56 | 0.05 | ||
| Avg | -0.71 | -0.64 | -0.32 | ||
| Low | -0.80 | -0.74 | -0.58 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.